Efectos adversos cutáneos del imatinib (inhibidor de la tirosín cinasa)

McArthur, 2004, Molecularly targeted treatment for dermatofibrosarcoma protuberans, Semin Oncol, 3, 30, 10.1053/j.seminoncol.2004.03.038 Olivieri, 2009, Imatinib for refractory chronic graft-versus-host disease with fibrotic features, Blood, 114, 709, 10.1182/blood-2009-02-204156 Bournia, 2013, Therapeutic inhibition of tyrosine kinases in systemic sclerosis: A review of published experience on the first 108 patients treated with imatinib, Semin Arthritis Rheum, 42, 377, 10.1016/j.semarthrit.2012.06.001 Ustun, 2011, Tyrosine kinase inhibitors in the treatment of systemic mastocytosis, Leuk Res, 35, 1143, 10.1016/j.leukres.2011.05.006 Botella-Estrada, 2012, KIT mutations in a series of melanomas and their impact on treatment with imatinib, Actas Dermosifiliogr, 103, 838, 10.1016/j.ad.2011.10.019 Hochhaus, 2009, Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia, Leukemia, 23, 1054, 10.1038/leu.2009.38 Common Terminology Criteria for Adverse Events (CTCAE). Version 4.0. Cancer Therapy Evaluation Program [Internet]. Bethesda: National Cancer Institute [citado 31 Oct 2012]. Disponible en: http://evs-nci.nih.gov/ftpl/CTCAE/About.html Thanopoulou, 2012, The safety profile of imatinib in CML and GIST: Long-term considerations, Arch Toxicol, 86, 1, 10.1007/s00204-011-0729-7 Druker, 2006, Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia, N Engl J Med, 355, 2408, 10.1056/NEJMoa062867 Saglio, 2010, Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia, N Engl J Med, 362, 2251, 10.1056/NEJMoa0912614 Kantarjian, 2010, Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia, N Engl J Med, 362, 2260, 10.1056/NEJMoa1002315 Kantarjian, 2007, Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: A randomized phase 2 trial, Blood, 109, 5143, 10.1182/blood-2006-11-056028 Amitay-Laish, 2011, Adverse cutaneous reactions secondary to tyrosine kinase inhibitors including imatinib mesylate, nilotinib, and dasatinib, Dermatol Ther, 24, 386, 10.1111/j.1529-8019.2011.01431.x Basso, 2009, Skin and oral lesions associated to imatinib mesylate therapy, Support Care Cancer, 17, 465, 10.1007/s00520-008-0536-8 Valeyrie, 2003, Adverse cutaneous reactions to imatinib (STI-571) in Philadelphia chromosome positive leukemias: a prospective study of 54 patients, J Am Acad Dermatol, 48, 201, 10.1067/mjd.2003.44 Mauro, 2009, Management of drug toxicities in chronic myeloid leukaemia, Best Pract Res Clin Haematol, 22, 409, 10.1016/j.beha.2009.06.001 Verweij, 2004, Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: Randomised trial, Lancet, 364, 1127, 10.1016/S0140-6736(04)17098-0 Brouard, 2001, Cutaneous reactions to STI571, N Engl J Med, 345, 618, 10.1056/NEJM200108233450814 Marin, 2002, The use of imatinib (STI571) in chronic myeloid leukemia: Some practical considerations, Haematologica, 87, 979 O’Brien, 2011, NCCN Task Force Report. Tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemia, J Natl Compr Canc Netw, 9, S1, 10.6004/jnccn.2011.0125 Nelson, 2006, Desensitization to imatinib in patients with leukemia, Ann Allergy Asthma Immunol, 97, 216, 10.1016/S1081-1206(10)60016-6 Guilhot, 2004, Indications for imatinib mesylate therapy and clinical management, Oncologist, 9, 271, 10.1634/theoncologist.9-3-271 Hensley, 2003, Imatinib treatment specific issues: related to safety, fertility and pregnancy, Semin Hematol, 40, 21, 10.1053/shem.2003.50038 Scheinfeld, 2006, Imatinib mesylate and dermatology, part 2: A review of the cutaneous side effects of imatinib mesylate, J Drugs Dermatol, 5, 228 Cornelison, 2012, Managing side effects of tyrosine kinase inhibitor therapy to optimize adherence in patients with chronic myeloid leukemia: The role of the midlevel practitioner, J Support Oncol, 10, 14, 10.1016/j.suponc.2011.08.001 Kuraishi, 2010, Lichenoid drug eruption with palmoplantar hyperkeratosis due to imatinib mesylate: a case report and a review of the literature, Acta DermVenereol, 90, 73 Kawakami, 2009, Cutaneous lichenoid eruption caused by imatinib mesylate in a Japanese patient with chronic myeloid leukaemia, Acta DermVenereol, 89, 325 Ena, 2004, Oral lichenoid eruption secondary to imatinib (Glivec), J Dermatolog Treat, 15, 253, 10.1080/09546630410015556 Prabhash, 2005, Lichenoid eruption due to imatinib, Indian J Dermatol Venereol Leprol, 71, 287, 10.4103/0378-6323.16627 Dalmau, 2006, Imatinib-associated lichenoid eruption: acitretin treatment allows maintained antineoplastic effect, Br J Dermatol, 154, 1213, 10.1111/j.1365-2133.2006.07276.x Grossman, 2004, Hypopigmentation from imatinib mesylate (Gleevec), J Pediatr Hematol Oncol, 26, 214, 10.1097/00043426-200403000-00016 Arora, 2004, Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate, Ann Oncol, 15, 358, 10.1093/annonc/mdh068 Etienne, 2002, Imatinib mesylate and gray hair, N Engl J Med, 347, 446, 10.1056/NEJM200208083470614 Resende, 2012, Imatinib-associated hyperpigmentation of the palate in post-HSCT patient, J Craniomaxillofac Surg, 40, e140, 10.1016/j.jcms.2011.07.010 Mattsson, 2011, Oral pigmentation in the hard palate associated with imatinib mesylate therapy: A report of three cases, Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 111, e12, 10.1016/j.tripleo.2010.11.006 McPherson, 2009, Imatinib-associated hyperpigmentation, a side effect that should be recognized, J Eur Acad Dermatol Venereol, 23, 82, 10.1111/j.1468-3083.2008.02706.x Wehrle-Haller, 2003, The role of Kit-ligand in melanocyte development and epidermal homeostasis, Pigment Cell Res, 16, 287, 10.1034/j.1600-0749.2003.00055.x Kleinegger, 2000, Oral mucosal hyperpigmentation secondary to antimalarial drug therapy, Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 90, 189, 10.1067/moe.2000.106340 Woo, 2007, Exacerbation of psoriasis in a chronic myelogenous leukemia patient treated with imatinib, J Dermatol, 34, 724, 10.1111/j.1346-8138.2007.00369.x Cheng, 2009, Management of imatinib-related exacerbation of psoriasis in a patient with a gastrointestinal stromal tumour, Australas J Dermatol, 50, 41, 10.1111/j.1440-0960.2008.00495.x Deguchi, 2006, Imatinib mesylate causes palmoplantar hyperkeratosis and nail dystrophy in three patients with chronic myeloid leukaemia, Br J Dermatol, 154, 1216, 10.1111/j.1365-2133.2006.07262.x Miyagawa, 2002, Improvement of psoriasis during imatinib therapy in a patient with a metastatic gastrointestinal stromal tumour, Br J Dermatol, 147, 406, 10.1046/j.1365-2133.2002.497217.x Thachil, 2009, T-regulatory cell response in psoriasis and changes with imatinib therapy, Clin Exp Dermatol, 34, e1022, 10.1111/j.1365-2230.2009.03696.x Konstantopoulos, 2002, Pityriasis rosea associated with imatinib (STI571, Gleevec), Dermatology, 205, 172, 10.1159/000063900 Brazzelli, 2005, Pityriasis rosea-like eruption during treatment with imatinib mesylate: description of 3 cases, J Am Acad Dermatol, 5, 240, 10.1016/j.jaad.2004.10.888 Cho, 2011, Pityriasis rosea-like drug eruption induced by imatinib mesylate (Gleevec™), Ann Dermatol, 23, 360, 10.5021/ad.2011.23.S3.S360 Dib, 2005, Neutrophilic eccrine hidradenitis induced by imatinib mesylate (Gleevec) therapy, Leuk Res, 29, 233, 10.1016/j.leukres.2004.05.015 Brouard, 2001, Acute generalized exanthematous pustulosis associated with STI571 in a patient with chronic myeloid leukemia, Dermatology, 203, 57, 10.1159/000051705 Schwarz, 2002, Imatinib-induced acute generalized exanthematous pustulosis (AGEP) in two patients with chronic myeloid leukemia, Eur J Haematol, 69, 254, 10.1034/j.1600-0609.2002.02830.x Gambillara, 2005, Severe pustular eruption associated with imatinib and voriconazole in a patient with chronic myeloid leukemia, Dermatology, 211, 363, 10.1159/000088510 Vidal, 2002, Sti571-induced Stevens-Johnson syndrome, Br J Haematol, 119, 274, 10.1046/j.1365-2141.2002.37133.x Pavithran, 2005, Imatinib induced Stevens-Johnson syndrome: Lack of recurrence following re-challenge with a lower dose, Indian J Dermatol Venereol Leprol, 71, 288, 10.4103/0378-6323.16628 Hsieh, 2009, Stevens-Johnson syndrome induced by combination of imatinib and allopurinol, Chemotherapy, 55, 197, 10.1159/000218097 Hsiao, 2002, Stevens-Johnson syndrome after treatment with STI571: A case report, Br J Haematol, 117, 620, 10.1046/j.1365-2141.2002.03499.x Mahapatra, 2007, Imatinib-induced Stevens-Johnson syndrome: recurrence after re-challenge with a lower dose, Ann Hematol, 86, 537, 10.1007/s00277-007-0265-y Ayirookuzhi, 2005, Imatinib-induced Sweet syndrome in a patient with chronic myeloid leukemia, Arch Dermatol, 141, 368, 10.1001/archderm.141.3.368 Liu, 2004, Sweet's syndrome with CML cell infiltration of the skin in a patient with chronic-phase CML while taking imatinib mesylate, Leuk Res, 28, 61, 10.1016/S0145-2126(03)00257-1 Drummond, 2003, A spectrum of skin reactions caused by the tyrosine kinase inhibitor imatinib mesylate (STI571, Glivec), Br J Haematol, 120, 911, 10.1046/j.1365-2141.2003.04151_4.x De Masson, 2011, Recurrent neutrophilic panniculitis in a patient with chronic myelogenous leukaemia treated with imatinib mesilate and dasatinib, Ann Dermatol Venereol, 138, 135, 10.1016/j.annder.2010.11.009 Assouline, 2006, Panniculitis during dasatinib therapy for imatinib-resistant chronic myelogenous leukemia, N Engl J Med, 354, 2623, 10.1056/NEJMc053425 Ugurel, 2003, Panniculitis in a patient with chronic myelogenous leukaemia treated with imatinib, Br J Dermatol, 149, 678, 10.1046/j.1365-2133.2003.05594.x García-Romero, 2012, Imatinib mesylate-induced neutrophilic folliculitis in a teenager, Int J Dermatol, 51, 1529, 10.1111/j.1365-4632.2010.04774.x Schaich, 2003, Severe epidermal necrolysis after treatment with imatinib and consecutive allogeneic hematopoietic stem cell transplantation, Ann Hematol, 82, 303, 10.1007/s00277-003-0643-z Rousselot, 2003, Photosensitization in chronic myelogenous leukemia patients treated with imatinib mesylate, Br J Haematol, 120, 1091, 10.1046/j.1365-2141.2003.04208_3.x Brazzelli, 2012, Photoinduced dermatitis and oral lichenoid reaction in a chronic myeloid leukemia patient treated with imatinib mesylate, Photodermatol Photoimmunol Photomed, 28, 2, 10.1111/j.1600-0781.2011.00621.x Clark, 2003, Mycosis fungoides-like reaction in a patient treated with Gleevec, J Cutan Pathol, 30, 279, 10.1046/j.0303-6987.2003.053.x Ho, 2003, Precipitation of porphyria cutanea tarda by imatinib mesylate?, Br J Haematol, 121, 375, 10.1046/j.1365-2141.2003.04277.x Timmer-de Mik, 2009, Imatinib-induced pseudoporphyria, Clin Exp Dermatol, 34, 705, 10.1111/j.1365-2230.2008.02985.x Reddy, 2012, Skin fragility and blistering secondary to imatinib, Clin Exp Dermatol, 37, 572, 10.1111/j.1365-2230.2011.04289.x Verma, 2010, Skin fragility and blistering with imatinib mesylate, J Eur Acad Dermatol Venereol, 24, 496, 10.1111/j.1468-3083.2009.03456.x